KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Deferred Taxes (2021 - 2023)

Moderna (MRNA) has disclosed Deferred Taxes for 3 consecutive years, with -$33.0 million as the latest value for Q4 2023.

  • On a quarterly basis, Deferred Taxes rose 61.63% to -$33.0 million in Q4 2023 year-over-year; TTM through Sep 2024 was -$33.0 million, a 103.89% decrease, with the full-year FY2023 number at $901.0 million, up 261.18% from a year prior.
  • Deferred Taxes was -$33.0 million for Q4 2023 at Moderna, down from $1.5 billion in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $1.5 billion in Q3 2023 to a low of -$310.0 million in Q1 2023.
  • A 3-year average of $2.0 million and a median of -$91.5 million in 2022 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: tumbled 945.45% in 2022, then soared 1609.28% in 2023.
  • Moderna's Deferred Taxes stood at -$229.0 million in 2021, then skyrocketed by 62.45% to -$86.0 million in 2022, then soared by 61.63% to -$33.0 million in 2023.
  • Per Business Quant, the three most recent readings for MRNA's Deferred Taxes are -$33.0 million (Q4 2023), $1.5 billion (Q3 2023), and -$220.0 million (Q2 2023).